MedTrace Logo

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

NCT02658825 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-02-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of JNJ-63623872 on the QT/QTc interval at supratherapeutic exposure in healthy participants (Panel 2).

Conditions

  • Healthy

Interventions

DRUG

JNJ-63623872 2400 milligram (mg)

Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.

DRUG

JNJ-63623872 3000 mg

Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.

DRUG

JNJ-63623872

Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.

DRUG

Moxifloxacin

Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.

DRUG

Placebo (Matching with JNJ-63623872 2400 mg)

Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.

DRUG

Placebo (Matching with JNJ-63623872 3000 mg)

Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.

DRUG

Placebo (Matching with JNJ-63623872 Dose)

Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.

DRUG

Placebo (Matching with Moxifloxacin)

Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02658825 on ClinicalTrials.gov